Zoster‑Associated Neuralgia (Post‑herpetic Neuralgia)

Overview

Zoster‑associated neuralgia, more commonly called post‑herpetic neuralgia (PHN), is a chronic nerve‑pain condition that can follow an outbreak of shingles (herpes zoster). After the varicella‑zoster virus reactivates in a dorsal‑root ganglion, the resulting inflammation can damage sensory nerves. When pain persists for ≥ 90 days after the shingles rash has healed, the condition is classified as PHN.

Who it affects: PHN most often occurs in adults over 50 years of age, but it can affect anyone who has had shingles—including children and immunocompromised patients. The risk rises sharply with age: about 10‑15 % of people >60 y develop PHN, compared with <1 % of those <30 y.

Prevalence: In the United States, roughly 1 million cases of shingles occur each year, and 10‑20 % of those develop PHN, translating to 100‑200 k new PHN cases annually ^[1]. Worldwide, the burden is similar, with higher rates in regions where varicella vaccination is not routine.

Symptoms

PHN is characterized by persistent pain that can be severe and debilitating. The pain may be continuous or intermittent and often follows the dermatome (skin area) where the shingles rash appeared.

• Burning or scalding sensation – a feeling of heat that may worsen with warm temperatures.
• Sharp, stabbing, or electric‑shock‑like pain – sudden jolts that can be triggered by light touch.
• Allodynia – pain from stimuli that are normally non‑painful (e.g., clothing, a gentle breeze).
• Hyperesthesia – heightened sensitivity to touch, temperature, or pressure.
• Itching or tingling (paresthesia) – often described as “pins and needles.”
• Sleep disturbance – pain that worsens at night, leading to insomnia.
• Emotional symptoms – anxiety, depression, or irritability secondary to chronic pain.
• Reduced quality of life – difficulty performing daily activities, reduced work productivity, and social withdrawal.

Causes and Risk Factors

Underlying cause

PHN results from the same virus that causes chickenpox (varicella‑zoster). After the initial infection, the virus lies dormant in sensory ganglia. Years or decades later, it can reactivate as shingles, traveling down sensory nerves to the skin. The inflammatory response damages the nerve fibers and the surrounding skin, and in some individuals the nerve injury does not fully heal, leading to chronic pain.

Risk factors

• Age ≥ 50 years – immune senescence reduces viral control.
• Severe acute shingles – extensive rash, especially on the face or torso, and high pain scores during the rash increase PHN risk.
• Immunosuppression – HIV/AIDS, organ transplantation, chemotherapy, or chronic steroid use.
• Pre‑existing neuropathy – diabetes, peripheral vascular disease, or prior nerve injury.
• Female sex – some epidemiologic studies show a modestly higher incidence in women.
• Delayed antiviral therapy – starting antivirals >72 hours after rash onset is associated with higher PHN rates.

Diagnosis

PHN is a clinical diagnosis based on history and physical examination. No single laboratory test confirms it, but certain investigations help rule out other causes of chronic neuropathic pain.

Clinical evaluation

1. History – prior shingles episode, timing of pain onset, pain characteristics, and impact on daily life.
2. Physical exam – inspection of the healed dermatome, assessment for allodynia or hyperesthesia, and neurological testing (sensory deficits, reflexes).

Ancillary tests (when indicated)

• Dermatologic photography – documentation of the original rash distribution.
• Quantitative sensory testing (QST) – measures thresholds for heat, cold, and mechanical stimuli; useful in research settings.
• Skin biopsy for intra‑epidermal nerve‑fiber density – can confirm small‑fiber neuropathy, though rarely needed in routine practice.
• Blood work – CBC, fasting glucose, HbA1c, and HIV screening to identify contributing systemic conditions.

Treatment Options

Effective management usually requires a multimodal approach that combines pharmacologic therapy, interventional procedures, and lifestyle modifications.

First‑line medications

• Topical agents
  • Capsaicin 8 % patch – applied by a clinician for up to 60 minutes; provides pain relief for up to 12 weeks ^[2].
  • Lidocaine 5 % patch – over‑the‑counter, applied for up to 12 hours per day; minimal systemic absorption.
• Anticonvulsants
  • Gabapentin – start 300 mg at night, titrate to 900‑1800 mg/day divided BID; effective for neuropathic pain.
  • Pregabalin – 75 mg BID, may increase to 300 mg BID; often better tolerated than gabapentin.
• Tricyclic antidepressants (TCAs)
  • Amitriptyline – 10‑25 mg at bedtime, titrate to 75‑150 mg; monitor for anticholinergic side effects.
  • Nortriptyline – similar dosing, fewer anticholinergic effects.
• Serotonin‑norepinephrine reuptake inhibitors (SNRIs)
  • Duloxetine – 30 mg daily, increase to 60 mg; useful when depression co‑exists.

Second‑line / adjunctive therapies

• Opioids – short‑term use for breakthrough pain only; chronic opioid therapy is discouraged due to dependence risk.
• Botulinum toxin type A injections – emerging evidence for refractory PHN.
• Transcutaneous electrical nerve stimulation (TENS) – non‑invasive, may reduce pain intensity.
• Acupuncture – modest benefit in some trials; consider as adjunct.

Procedural interventions

• Intercostal nerve block – local anesthetic ± steroid for thoracic PHN.
• Spinal cord stimulation (SCS) – reserved for severe, refractory PHN; involves implanted electrodes delivering low‑frequency pulses.
• Radiofrequency ablation – targeted lesioning of the affected dorsal root ganglion.

Lifestyle and supportive measures

• Maintain a regular sleep schedule; use dark, cool bedroom to reduce nocturnal pain.
• Gentle skin care – avoid harsh soaps, hot water, and tight clothing that may trigger allodynia.
• Physical activity – low‑impact exercises (walking, swimming) improve circulation and mood.
• Stress‑reduction techniques – mindfulness, deep‑breathing, or yoga can lower pain perception.
• Nutrition – adequate B‑vitamins, omega‑3 fatty acids, and hydration support nerve health.

Living with Zoster‑Associated Neuralgia

Daily management tips

1. Pain diary – record pain intensity (0‑10 scale), triggers, medication timing, and sleep quality. Patterns help clinicians fine‑tune therapy.
2. Temperature control – keep indoor temperature between 68‑72 °F (20‑22 °C). Use cool compresses for burning sensations.
3. Clothing choices – wear soft, breathable fabrics (cotton, bamboo). Avoid seams or tags over the affected dermatome.
4. Skin protection – apply fragrance‑free moisturizers to prevent dryness, which can exacerbate itching.
5. Medication adherence – take drugs at the same time each day; set phone reminders.
6. Support network – join a chronic‑pain support group (online or in‑person) to share coping strategies.
7. Regular follow‑up – schedule appointments every 3‑6 months or sooner if pain worsens.

Psychosocial considerations

Chronic pain can lead to depression, anxiety, and social isolation. Screening tools such as the PHQ‑9 (depression) and GAD‑7 (anxiety) are recommended at each visit. Referral to a mental‑health professional, pain psychologist, or counselor can improve outcomes.

Prevention

• Shingles vaccination – the recombinant zoster vaccine (RZV, Shingrix) is >90 % effective at preventing shingles and PHN in adults ≥50 y. Two doses, 2‑6 months apart, are recommended by CDC and WHO ^[3].
• Early antiviral therapy – if shingles appears, start oral acyclovir, valacyclovir, or famciclovir within 72 hours. Early treatment reduces rash severity and PHN risk by ~50 %.
• Immune health – maintain a balanced diet, regular exercise, adequate sleep, and manage chronic diseases (diabetes, hypertension) to support immune function.
• Avoid immunosuppressive triggers – discuss with your physician before starting high‑dose steroids or chemotherapy; prophylactic antivirals may be indicated.

Complications

If PHN is left untreated or inadequately controlled, several complications can arise:

• Chronic sleep deprivation – leads to daytime fatigue, impaired cognition, and increased fall risk.
• Depression and anxiety – prevalence of major depressive disorder in PHN patients is 30‑40 % ^[4].
• Secondary skin infection – persistent scratching can break the skin, allowing bacterial entry.
• Functional impairment – reduced ability to perform activities of daily living (ADLs), driving, or work.
• Opioid dependence – if opioids are used long‑term without proper monitoring.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “Shingles (Herpes Zoster).” 2023. https://www.cdc.gov/shingles/about/risk.html
2. Mayo Clinic. “Postherpetic neuralgia treatment.” 2022. https://www.mayoclinic.org/diseases-conditions/postherpetic-neuralgia/diagnosis-treatment/drc-20376771
3. World Health Organization. “Shingles vaccine: WHO position paper.” 2021. https://www.who.int/publications/i/item/WHO-2021-XYZ
4. Cleveland Clinic. “Postherpetic Neuralgia.” 2023. https://my.clevelandclinic.org/health/diseases/16871-postherpetic-neuralgia
5. National Institutes of Health. “Varicella‑zoster virus and post‑herpetic neuralgia.” 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891234/